
Aditxt, Inc. — Investor Relations & Filings
Aditxt, Inc. is an innovation company focused on acquiring, developing, and deploying promising health technologies. Its business model involves acquiring disruptive and scalable companies, leveraging its business acceleration platform to drive growth, and monetizing assets through various strategies including mergers, sales, and licenses. The company's portfolio of programs targets significant health challenges. Current programs include Adimune, focused on autoimmunity; Pearsanta, for early cancer detection; and Adivue, for neurological diagnostics. Aditxt also has planned programs and proposed acquisitions in areas such as reproductive health.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - Aditxt, Inc. (0001726711) (Filer) | 2026-04-14 | English | |
| S-3 - Aditxt, Inc. (0001726711) (Filer) | 2026-04-11 | English | |
| 8-K/A - Aditxt, Inc. (0001726711) (Filer) | 2026-04-07 | English | |
| DEF 14A - Aditxt, Inc. (0001726711) (Filer) | 2026-04-03 | English | |
| 8-K - Aditxt, Inc. (0001726711) (Filer) | 2026-04-02 | English | |
| 8-K - Aditxt, Inc. (0001726711) (Filer) | 2026-03-30 | English |
Browse filings by year
9 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
11 filings
| |||||
| 34484140 | 8-K - Aditxt, Inc. (0001726711) (Filer) | 2026-04-14 | English | ||
| 34402623 | S-3 - Aditxt, Inc. (0001726711) (Filer) | 2026-04-11 | English | ||
| 33743863 | 8-K/A - Aditxt, Inc. (0001726711) (Filer) | 2026-04-07 | English | ||
| 33302978 | DEF 14A - Aditxt, Inc. (0001726711) (Filer) | 2026-04-03 | English | ||
| 33158825 | 8-K - Aditxt, Inc. (0001726711) (Filer) | 2026-04-02 | English | ||
| 33087919 | 8-K - Aditxt, Inc. (0001726711) (Filer) | 2026-03-30 | English | ||
| 33066090 | 424B5 - Aditxt, Inc. (0001726711) (Filer) | 2026-03-27 | English | ||
| 31498298 | 8-K Filing | 2026-02-13 | English | ||
| 31498392 | 8-K Filing | 2026-01-30 | English | ||
| 31498344 | SCHEDULE 13G Filing | 2026-01-30 | English | ||
| 31498281 | 8-K Filing | 2026-01-28 | English | ||
|
2025
4 filings
| |||||
| 13087095 | Director's Dealing 2025 | 2025-12-19 | English | ||
| 13087096 | DEFINITIVE PROXY STATEMENT | 2025-12-16 | English | ||
| 13087097 | PROSPECTUS SUPPLEMENT | 2025-12-12 | English | ||
| 13087099 | REVISED PRELIMINARY PROXY STATEMENT | 2025-12-05 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
NewAmsterdam Pharma Co N.V.
A clinical-stage biopharma developing therapies for metabol…
|
NAMS | NL | Professional, scientific and te… |
|
NEXALIS THERAPEUTICS LTD
Develops small molecule therapies for chronic inflammatory …
|
NX1 | AU | Professional, scientific and te… |
|
NextGen Biomed Ltd.
Develops novel therapeutic delivery systems and pain-free a…
|
NXGN | IL | Professional, scientific and te… |
|
NEXTURNBIOSCIENCE Co., LTD
Manufacturer of CNC automatic lathes and ultra-precision co…
|
089140 | KR | Professional, scientific and te… |
|
NFL Biosciences
Biopharmaceutical company developing botanical drug candida…
|
ALNFL | FR | Professional, scientific and te… |
|
NGeneBio Co., Ltd.
Develops NGS-based molecular diagnostic products and softwa…
|
354200 | KR | Professional, scientific and te… |
|
Nicox S.A.
Ophthalmology company developing therapies based on a nitri…
|
COX | FR | Professional, scientific and te… |
|
Nirvana Life Sciences Inc
Developing non-addictive psilocybin therapeutics to treat a…
|
NIRV | CA | Professional, scientific and te… |
|
NLS Pharmaceutics Ltd.
Clinical-stage biopharma firm developing therapies for rare…
|
NLSP | US | Professional, scientific and te… |
|
NovoCure Ltd
Develops a non-invasive cancer therapy using electric field…
|
NVCR | JE | Professional, scientific and te… |
Aditxt, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35447/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35447 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35447 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35447 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35447}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Aditxt, Inc. (id: 35447)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.